Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Biotechnology

Healthcare
$27.61 -1.93%

-$0.51 today

Market cap
$3.49B
Beta
1.52
P/E (TTM)
-1400.0
EPS (TTM)
-$0.02
52W Low $13.06High $31.77

Volume 0.84M

Average 1.61M

ARQT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income turns positive

Q2 FY2026 net income was $15.01M, compared with -$15.89M a year earlier. Trailing-twelve-month net income was $28.52M. Over 3 fiscal years it compounded at -62.7% a year.

Context

  • Net income amounted to 4.3% of revenue in FY2025, down 67.0 pp from a year earlier.
  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of $43.52M (+369.6%) for the fiscal year ending Dec 2026, a step up from the -88.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$15.01M+232.9% QoQ
Last fiscal yearDec 2025
-$16.14M-88.5% YoY
LTMJun 2026
$28.52M+130.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+194.5%+232.4%+37.9 pp
1 year-88.5%+369.6%+458.1 pp
3-year CAGR-62.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(16.14M) USD
Year-over-year change
+88.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ARQT compares with its peers on the latest reported figures

  • ARQT's LTM Jun 2026 net income of $28.52M is the 3rd largest of the 6 companies compared; the peer median is $27.37M.
  • Its year-over-year change of +130.6% is the highest of 3, against a peer median of -49.5%.
  • Net income amounts to 6.1% of revenue for ARQT, versus a peer median of 759.9%.
ARQT Competitors Peer median
Net Income for ARQT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EVMNEvommune, Inc.LTM Mar 2026$75.99M ——759.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M -46.5%-9.3%832.6%
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$28.52M +130.6%-62.7%6.1%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$27.37M -52.6%-18.3%—
SLGLSol-Gel Technologies Ltd.LTM Jun 2024$14.92M —-25.7%227.4%
TTRXTurn Therapeutics Inc.LTM Mar 2026$3.84M ———
Peer median (excluding ARQT) $27.37M-49.5%-18.3%759.9%

Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(206.36M)(311.46M)(262.14M)(140.04M)(16.14M)
Depreciation & Amortization454K934K750K2.6M4.67M
Deferred Income Tax3.45M0000
Stock-Based Compensation23.89M32.68M38.81M41.73M40.36M
Change in Working Capital3.62M(10.18M)(23.5M)(15.08M)(34.83M)
Accounts Receivables0(8.46M)(17.35M)(47.26M)(73.16M)
Inventory0(7.51M)(5.62M)(400K)(7.33M)
Accounts Payables245K1.57M3.15M2.23M(1.69M)
Other Working Capital3.38M4.23M(3.68M)30.35M47.36M
Other Non-Cash Items309K30.3M(979K)(1.37M)314K
Operating Cash Flow(174.63M)(257.72M)(247.06M)(112.16M)(5.63M)
Capital Expenditures(995K)(23.28M)(428K)(143K)(686K)
Acquisitions (Net)74.96M22.95M000
Purchases of Investments(292.51M)(415.39M)(225.84M)(254.82M)(246.99M)
Sales of Investments217.55M351.47M406.5M288.78M227.42M
Other Investing Activities(74.96M)(22.95M)0(5M)(10M)
Investing Cash Flow(75.95M)(87.2M)180.23M28.82M(30.25M)
Debt Repayment73.99M125M0(100M)0
Common Stock Issued207.49M176.05M98.9M161.68M6.97M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities470K751K2.42M4.52M0
Financing Cash Flow281.95M301.8M101.32M66.2M6.97M
Effect of Forex Changes00(50K)(235K)168K
Net Change in Cash31.37M(43.12M)34.45M(17.37M)(28.74M)
Free Cash Flow(175.62M)(281M)(247.49M)(112.3M)(6.31M)

Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Intrinsic Alpha fair value

Locked

Current Price

$27.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.